Please use this identifier to cite or link to this item:
Title: Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Authors: Mulligan, Stephen
Karlsson, Karin
Strömberg, Matts
Jønsson, Viggo
Gill, Devinder
Hammerström, Jens
Hertzberg, Mark
McLennan, Roger
Uggla, Bertil
Norman, John
Walvik, Jonas
Sundström, Gunnel
Hemming, Johansson
Brandberg, Yvonne
Liliemark, Jan
Juliusson, Gunnar
Issue Date: 2014
Publisher: Informa
Place of publication: London, United Kingdom
Publication Title: Leukemia & Lymphoma
Volume: 55
Issue: 12
Start Page: 2769
End Page: 2777
Abstract: We conducted a randomized phase III trial to compare the efficacy and safety of two purine analogs, cladribine and fludarabine, with high-dose chlorambucil, in patients with previously untreated chronic lymphocytic leukemia (CLL). Between 1997 and 2004, 223 patients with CLL were randomly assigned to cladribine, fludarabine or chlorambucil, for six cycles of therapy with frequent health-related quality of life assessments. There was no statistical difference for the primary endpoint of overall response with cladribine (70%), fludarabine (67%) and chlorambucil (59%), or complete remission (12%, 7% and 8%), respectively. However, the median progression-free survival (25, 10, 9 months) and median time to second treatment (40, 22, 21 months) were superior with cladribine. There was no significant difference in overall survival (96, 82 and 91 months), nor in toxicity or HRQoL assessments. Monotherapy with cladribine gives superior PFS and longer response duration than fludarabine and chlorambucil as first-line treatment of CLL.
ISSN: 1042-8194
Internal ID Number: 00705
Type: Journal Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.